Related references
Note: Only part of the references are listed.Harnessing cytokines and chemokines for cancer therapy
David J. Propper et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Therapeutic antibodies - natural and pathological barriers and strategies to overcome them
Yara Al Ojaimi et al.
PHARMACOLOGY & THERAPEUTICS (2022)
Engineering interferons and interleukins for cancer immunotherapy
Patrick G. Holder et al.
ADVANCED DRUG DELIVERY REVIEWS (2022)
Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy
Jin-Qing Liu et al.
JOURNAL OF CONTROLLED RELEASE (2022)
Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8+ T cells for cancer immunotherapy
Keunok Jung et al.
MOLECULAR CANCER (2022)
A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors
Yanling Wu et al.
MOLECULAR THERAPY (2022)
Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity
Jung-Eun Kim et al.
FRONTIERS IN IMMUNOLOGY (2021)
Engineered antibody fusion proteins for targeted disease therapy
Aliyah B. Silver et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2021)
Dissecting the impact of target-binding kinetics of protein binders on tumor localization
Yunjin Song et al.
ISCIENCE (2021)
NHS-IL12, a Tumor-Targeting Immunocytokine
John W. Greiner et al.
IMMUNOTARGETS AND THERAPY (2021)
Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress
Ivan S. Pires et al.
ADVANCED THERAPEUTICS (2021)
A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells
Keunok Jung et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Critical Issues in the Development of Immunotoxins for Anticancer Therapy
Ji-Sun Kim et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Increased Tumor Penetration of Single-Domain Antibody-Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models
Ian Nessler et al.
CANCER RESEARCH (2020)
Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth
Seung-Min Shin et al.
SCIENCE ADVANCES (2020)
Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
Cornelia Hutmacher et al.
ADVANCED DRUG DELIVERY REVIEWS (2019)
A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors
Tiziano Ongaro et al.
JOURNAL OF BIOTECHNOLOGY (2019)
First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2019)
Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor
Ryo Tsumura et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells
Keunok Jung et al.
ONCOIMMUNOLOGY (2018)
Microsomal Prostaglandin E Synthase-1 Facilitates an Intercellular Interaction between CD4+ T Cells through IL-1β Autocrine Function in Experimental Autoimmune Encephalomyelitis
Takako Takemiya et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
ABodyBuilder: Automated antibody structure prediction with data-driven accuracy estimation
Jinwoo Leem et al.
MABS (2016)
Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins
Ji-Hee Ha et al.
FRONTIERS IN IMMUNOLOGY (2016)
Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
Alice Tzeng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma
Bart Hilvering et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2015)
New insights into IL-12-mediated tumor suppression
S. Tugues et al.
CELL DEATH AND DIFFERENTIATION (2015)
Enhancement of the Tumor Penetration of Monoclonal Antibody by Fusion of a Neuropilin-Targeting Peptide Improves the Antitumor Efficacy
Tae-Hwan Shin et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The immunocytokine NHS-IL12 as a potential cancer therapeutic
Jonathan Fallon et al.
ONCOTARGET (2014)
A Heterodimeric Fc-Based Bispecific Antibody Simultaneously Targeting VEGFR-2 and Met Exhibits Potent Antitumor Activity
Hye-Ji Choi et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Immunocytokines: a review of molecules in clinical development for cancer therapy
Thomas List et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2013)
The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel
Nadine Pasche et al.
CLINICAL CANCER RESEARCH (2012)
Crosstalk between Human IgG Isotypes and Murine Effector Cells
Marije B. Overdijk et al.
JOURNAL OF IMMUNOLOGY (2012)
IL-12 family cytokines: immunological playmakers
Dario A. A. Vignali et al.
NATURE IMMUNOLOGY (2012)
Humanized Mouse Model of Skin Inflammation Is Characterized by Disturbed Keratinocyte Differentiation and Influx of IL-17A Producing T Cells
Vivian L. de Oliveira et al.
PLOS ONE (2012)
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
Jun Fang et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors
Stephen I. Rudnick et al.
CANCER RESEARCH (2011)
A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma
Sarah M. Rudman et al.
CLINICAL CANCER RESEARCH (2011)
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Jenny Bostrom et al.
SCIENCE (2009)
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Greg M. Thurber et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models
Kin-Ming Lo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors
AJ Primeau et al.
CLINICAL CANCER RESEARCH (2005)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
Share Paper
